Patents Assigned to Socpra Sciences Sante Et Humaines
-
Publication number: 20230105935Abstract: Provided herein are antiviral compounds having the structure of Formula (I) and compositions thereof for use in the treatment of viral infection. In particular, the compounds of Formula (I) are capable of interfering with the export of viral mRNA processing as reflected in the altered accumulation of viral RNA isoforms as well as transport from the nucleus to the cytoplasm. Such compounds show a reduction of HIV, adenovirus and coronavirus infection of cells. The invention provides compounds that may be suitable for the treatment of HIV/AIDS.Type: ApplicationFiled: December 15, 2020Publication date: April 6, 2023Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINEInventors: David Scott Grierson, Maryam Zamiri, Peter K. Cheung, Benoit Chabot, Alan Walter Cochrane
-
Patent number: 11591366Abstract: The present invention provides a macrocyclic compound of formula (I) compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.Type: GrantFiled: June 18, 2018Date of Patent: February 28, 2023Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.Inventors: Éric Marsault, Marc Sousbie, Richard Leduc, Philippe Sarret, Jean-Michel Longpré, Élie Besserer-Offroy, Rebecca Brouillette, Michael Desgagné
-
Patent number: 11213597Abstract: It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.Type: GrantFiled: June 23, 2016Date of Patent: January 4, 2022Assignee: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Fernand Gobeil, Brigitte Guerin, Martin Lepage, Robert Sabbagh, David Fortin
-
Patent number: 10988505Abstract: The present application relates to a compound of formulae (I), (II) or (III) or a pharmaceutically acceptable salt thereof, methods and uses thereof for treating disorders associated with matriptase activity.Type: GrantFiled: December 21, 2017Date of Patent: April 27, 2021Assignee: SOCIÉTÉ DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUÉE SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.Inventors: Pierre-Luc Boudreault, Éloïc Colombo, Richard Leduc, Eric Marsault, Baptiste Plancq, Martin Richter
-
Publication number: 20190316211Abstract: It is provided a tumor promoting alternative splicing isoform of PACE4, named PACE4-alt CT, analytes specifically binding to PACE4-alt CT, such as antibodies, and use of same for detecting a cancer, such as prostate cancer. It is also provided a method treating a cancer in a patient comprising administering an inhibitor of PACE4-altCT to a patient in need thereof and a kit comprising an analyte specific reagent specifically binding to PACE4-altCT for detecting a cancer.Type: ApplicationFiled: November 29, 2017Publication date: October 17, 2019Applicant: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINEInventors: Robert DAY, Frédéric COUTURE, Robert SABBAGH
-
Patent number: 10208308Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flue infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and prevention orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.Type: GrantFiled: July 12, 2017Date of Patent: February 19, 2019Assignee: Socpra Sciences Sante Et Humaines S.E.C.Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
-
Patent number: 9809621Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.Type: GrantFiled: August 30, 2012Date of Patent: November 7, 2017Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Patent number: 9752149Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.Type: GrantFiled: November 17, 2015Date of Patent: September 5, 2017Assignee: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
-
Patent number: 9573974Abstract: Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided.Type: GrantFiled: January 8, 2014Date of Patent: February 21, 2017Assignee: LA SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA-SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Martin Fugére, Witold A. Neugebauer
-
Publication number: 20150141324Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.Type: ApplicationFiled: August 31, 2012Publication date: May 21, 2015Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Patent number: 8884181Abstract: The present disclosure relates to a method and a system for generating low-energy electrons in a biological material. The biological material is held in position by a support. Laser beam pulses are directed by a focusing mechanism toward a region of interest within the biological material. This generates filaments of low-energy electrons within the region of interest. The method and system may be used for radiotherapy, radiochemistry, sterilization, nanoparticle coating, nanoparticle generation, and like uses.Type: GrantFiled: March 5, 2013Date of Patent: November 11, 2014Assignee: SOCPRA-Sciences Sante et Humaines S.E.C.Inventors: Daniel Houde, Ridthee Meesat, Jean-François Allard, Tiberius Brastaviceanu
-
Publication number: 20140206622Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.Type: ApplicationFiled: August 30, 2012Publication date: July 24, 2014Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
-
Publication number: 20140086936Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.Type: ApplicationFiled: May 28, 2012Publication date: March 27, 2014Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
-
Patent number: 8546346Abstract: The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct sequence elements: (i) a nucleic acid sequence that is complementary to a specific region upstream of the splice site in the target pre-mRNA molecule; and (ii) an extension containing a protein binding site sequence element for covalently binding a protein; wherein the protein moiety comprises a protein capable of modulating splicing of the splice site upon binding with the protein binding site.Type: GrantFiled: November 14, 2008Date of Patent: October 1, 2013Assignee: La Societe de Commercialisation des Produits de la Recherche Appliquee Socpra-Sciences Sante et Humaines S.E.C.Inventors: Benoit Chabot, Jonathan Villemaire, Sherif Abou Elela, Faiz-ul Hassan Nasim
-
Publication number: 20120290519Abstract: The present disclosure relates to a method and an apparatus for identifying line-of-responses (LOR) of photons. A radiation detection machine measures the photons. LOR identification errors are then mitigated using pattern recognition of the measurements. In some embodiments, the photons may comprise positron annihilation photons, each position annihilation photon being associated with one or more scattered photons. In yet some embodiments, pattern recognition may be implemented in a neural network.Type: ApplicationFiled: October 28, 2011Publication date: November 15, 2012Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.CInventors: Rejean Fontaine, Jean-Baptiste Michaud, Charles-Antoine Brunet, Roger Lecomte
-
Patent number: 8262997Abstract: A blood counting device comprises a capillary conduit for drawing from a subject in which a radiotracer has previously been injected a quantity of blood in the micro-liter range to produce in the capillary conduit a flow of blood from which beta radiation is emitted. At least one direct beta radiation detector is placed closely adjacent to the capillary conduit. The direct beta radiation detector consists of a semiconductor photodiode which detects the beta radiation from the flow of blood when directly hit by this beta radiation.Type: GrantFiled: March 17, 2006Date of Patent: September 11, 2012Assignee: Société de Commercialisation des Produits de la Recherche Appliquée-Socpra Sciences Sante et Humaines S.E.C.Inventors: Laurence Convert, Jules Cadorette, David Lapointe, Roger Lecomte
-
Publication number: 20120122113Abstract: The present invention relates to the identification of secreted protein isoforms specific in ovarian cancer and methods for diagnosis or prognosis of ovarian cancer in a subject by detecting the secreted protein isoforms.Type: ApplicationFiled: April 14, 2010Publication date: May 17, 2012Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.Inventors: Panagiotis Prions, Julian Venables, Benoit Chabot, Sherif Abou Elela
-
Publication number: 20120093918Abstract: A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.Type: ApplicationFiled: April 26, 2010Publication date: April 19, 2012Applicant: SOCPRA - SCIENCES SANTE ET HUMAINESInventors: Léon Sanche, Gabriel Charest
-
Patent number: 8076453Abstract: The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B1 receptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery of chemotherapeutic substances across the blood brain barrier and within peripheral tissues for the treatment of tumors, capacity to protect and restore kidney, heart, brain and other organ functions, when given alone or in combination with other therapies in the treatment of hypertension, diabetes and other cardiovascular diseases particularly, but not limited to, atherosclerosis and arteriosclerosis. Formula (I): aay-aax-aa0-aa1-aa2-aa3-aa4-aa5-Ser6-Pro7-D-Phe8-X.Type: GrantFiled: May 31, 2006Date of Patent: December 13, 2011Assignee: Societe De Commercialisation Des Produits De La Recheche Appliquee-Socpra-Science Sante Et Humaines S.E.C.Inventors: Fernand Gobeil, Jr., Witold A. Neugebauer, Domenico Regoli, David Fortin
-
Patent number: 8053553Abstract: Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes.Type: GrantFiled: May 5, 2008Date of Patent: November 8, 2011Assignees: Socpra Sciences Sante Et Humaines, Illumina, Inc., Sanford-Burnham Medical Research InstituteInventors: Alex Strongin, Michal Lebl, Robert Day